Erin Cobain
Internal Medicine Hematology/Oncology
1500 E Medical Center Drive
Ann Arbor, Michigan 48109
Manage Your Profile
About
Erin F. Cobain, MD is a Clinical Associate Professor in the Division of Hematology/Oncology, where she specializes in the treatment of patients with breast cancer. She received her undergraduate degree from Davidson College, which she received a B.S. in Biology and graduated cum laude and Phi Beta Kappa. She received her medical degree from the University of Chicago Pritzker School of Medicine. She completed her Internal Medicine residency at the Hospital of the University of Pennsylvania, where she also served as Chief Medical Resident. Dr. Cobain completed her fellowship in Hematology/Oncology at the University of Michigan, where she was also Chief Fellow. She joined the faculty at the University of Michigan in 2016. Dr. Cobain’s research interest is primarily in the application of next-generation sequencing technology in oncology clinical practice. She also has an interest in the use of tumor biomarkers to direct and personalize patient care. She works in collaboration with the Michigan Oncology Sequencing Center (Mi-OncoSeq program) to study the clinical outcomes of patients with advanced malignancies undergoing comprehensive next-generation sequencing analysis of their tumors.
Links
Profile - University of Michigan Rogel Cancer Center
Qualifications
-
FellowUniversity of Michigan Medical School, Internal Medicine, Ann Arbor, United States
2013 - 2016
Other
-
Chief ResidentHospital of the University of Pennsylvania, Internal Medicine, Philadelphia, United States
2012 - 2013
Chief Resident
-
ResidentHospital of the University of Pennsylvania, Internal Medicine, Philadelphia, United States
2010 - 2012
Residency
-
InternHospital of the University of Pennsylvania, Internal Medicine, Philadelphia, United States
2009 - 2010
Internship
-
MDUniversity of Chicago Pritzker School of Medicine, 924 E. 57th Street, Room 104, Chicago, IL, 60637, United States
2005 - 2009
Center Memberships
-
Center MemberRogel Cancer Center
Research Overview
Next generation sequencing of tumor and blood to identify therapeutic targets for patients with advanced cancer
Next-generation sequencing of matched tumor and normal samples to identify inherited cancer susceptibility
Identification of tumor biomarkers in breast cancer that predict benefit from immunotherapy
Recent Publications
-
Wilbur HC, Cobain E, Wiesner GL, Davis EJ, Chugh R. 2022 Jun 13;Proceeding / Abstract / PosterMulticenter retrospective study of clinical genetic testing in patients with sarcoma.
-
Wilbur HC, Cobain E, Wiesner GL, Davis EJ, Chugh R. 2022 Jun 13;Proceeding / Abstract / PosterMulticenter retrospective study of clinical genetic testing in patients with sarcoma.
-
Cobain EF, Mooney CJ, Smith DC. TUMOR BOARD REVIEW: GUIDELINE AND CASE REVIEWS IN ONCOLOGY, SECOND EDITION, 2015 TUMOR BOARD REVIEW: GUIDELINE AND CASE REVIEWS IN ONCOLOGY, SECOND EDITION, 207 - 216.ChapterBladder Cancer
PMID: BC1DS -
2026 Feb 3;PresentationPrecision Medicine in Action: Tailoring Therapy for Eraly-Stage Hormone Receptor Positive (HR+)/HER2-Negative(HER2-) Breast Cancer with Genomic Profiling
-
2026 Feb 3;PresentationOptimal Treatment Strategies for CDK4/6 Inhibitor Resistant Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
-
Amir E, Kristoff T, Blaha C, Bender U, Kalinsky K, Cobain E. Am Soc Clin Oncol Educ Book, 2026 Jun; 46 (3): e520488Journal ArticleNavigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast Cancer.
DOI:10.1200/EDBK-26-520488 PMID: 42208010 -
Cobain E. 2026 Jun 10;PresentationctDNA in Early-stage Breast Cancer, Handling Requests and Results
-
Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. JCO Precis Oncol, 2026 Apr; 10 (4): e2501205Journal ArticleNivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
DOI:10.1200/PO-25-01205 PMID: 42060861